SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial Using HEMOPATCH

NCT ID: NCT02668978

Last Updated: 2019-09-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

170 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-31

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to assess the efficacy and safety of HEMOPATCH™ Sealing Hemostat in reducing the incidence and duration of air leaks after lung resection compared to standard techniques.

Hypothesis: "The routine application of HEMOPATCH Sealing Hemostat on the visceral pleura in lung resection areas, during lung resection procedures, is more EFFICIENT to reduce the incidence and duration of prolonged air leaks as compared to standard surgical measures."

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

LUNG DISEASES

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hemopatch™

Hemopatch™ sealing hemostat

Group Type EXPERIMENTAL

Hemopatch™ Sealing Hemostat

Intervention Type DEVICE

Hemopatch™ application over lung resection areas

Control

Standard surgical technique

Group Type ACTIVE_COMPARATOR

Standard surgical technique

Intervention Type PROCEDURE

Lung resuturing or restapling

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hemopatch™ Sealing Hemostat

Hemopatch™ application over lung resection areas

Intervention Type DEVICE

Standard surgical technique

Lung resuturing or restapling

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over the age of 18 years who are able to give their informed consent
* Patients undergoing lung resection surgery for either malignant or benign conditions including:

* Lobar and sublobar resections
* Open, video-assisted thoracoscopic or robotic surgeries
* Diagnostic or therapeutic procedures

Exclusion Criteria

* Traumatic pulmonary contusion or laceration
* Lung reduction surgery
* Planned removal of more than 10 lung lesions
* Pneumonectomy
* Known hypersensitivity to bovine protein
* Known hypersensitivity to Brilliant Blue FCF (E133)
* Presence of active infection
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Baxter BioScience

INDUSTRY

Sponsor Role collaborator

Quirón Madrid University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Javier MORADIELLOS

Associate Chief of Thoracic Surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Quirónsalud Madrid University Hospital

Pozuelo de Alarcón, Madrid, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SEALLS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PleuraSeal Pivotal Study (US)
NCT00748124 TERMINATED PHASE3
RejuvenAir Lobectomy for Safety and Histology
NCT02483052 COMPLETED PHASE1/PHASE2